NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Forecast, Price & News $1.56 +0.05 (+3.31%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$1.47▼$1.6050-Day Range$1.12▼$1.8252-Week Range$0.64▼$2.04Volume2.71 million shsAverage Volume2.88 million shsMarket Capitalization$270.93 millionP/E RatioN/ADividend YieldN/APrice Target$4.21 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Rigel Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside169.8% Upside$4.21 Price TargetShort InterestHealthy4.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.30) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector404th out of 981 stocksPharmaceutical Preparations Industry180th out of 462 stocks 3.2 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.21, Rigel Pharmaceuticals has a forecasted upside of 169.8% from its current price of $1.56.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.66% of the outstanding shares of Rigel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently decreased by 4.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RIGL. Previous Next 2.5 News and Social Media Coverage News SentimentRigel Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Rigel Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest27 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.43% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions73.88% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.30) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Rigel Pharmaceuticals (NASDAQ:RIGL) StockRigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.Read More Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Stock News HeadlinesJune 7, 2023 | finance.yahoo.comBullish Rigel Pharmaceuticals Insiders Rewarded As Their Investment Rises To US$1.5mJune 7, 2023 | finance.yahoo.comBullish Rigel Pharmaceuticals Insiders Rewarded As Their Investment Rises To US$1.5m \June 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 7, 2023 | finance.yahoo.comRigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AMLJune 6, 2023 | msn.comRigel spikes after peer reviewed data on leukemia drugJune 6, 2023 | finance.yahoo.comRigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood AdvancesJune 2, 2023 | americanbankingnews.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $4.21 Average Target Price from AnalystsJune 1, 2023 | finance.yahoo.comRigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual MeetingJune 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 31, 2023 | finance.yahoo.comRigel to Present at the Jefferies 2023 Global Healthcare ConferenceMay 22, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Rigel Pharmaceuticals (NASDAQ:RIGL)May 9, 2023 | americanbankingnews.comCantor Fitzgerald Weighs in on Rigel Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:RIGL)May 8, 2023 | americanbankingnews.comAnalysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Price Target at $4.21May 8, 2023 | americanbankingnews.comStockNews.com Lowers Rigel Pharmaceuticals (NASDAQ:RIGL) to HoldMay 5, 2023 | americanbankingnews.comB. Riley Comments on Rigel Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:RIGL)May 5, 2023 | americanbankingnews.comRigel Pharmaceuticals, Inc. to Post Q2 2023 Earnings of ($0.08) Per Share, HC Wainwright Forecasts (NASDAQ:RIGL)May 4, 2023 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Call TranscriptMay 3, 2023 | msn.comHC Wainwright & Co. Reiterates Rigel Pharmaceuticals (RIGL) Buy RecommendationMay 3, 2023 | finance.yahoo.comQ1 2023 Rigel Pharmaceuticals Inc Earnings CallMay 2, 2023 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q1 Loss decreases, beats estimatesMay 1, 2023 | americanbankingnews.comRigel Pharmaceuticals (RIGL) to Release Earnings on TuesdayMay 1, 2023 | americanbankingnews.comOrganon & Co. (NYSE:OGN) versus Rigel Pharmaceuticals (NASDAQ:RIGL) Head to Head AnalysisApril 26, 2023 | finance.yahoo.comEarnings Preview: Pacira (PCRX) Q1 Earnings Expected to DeclineApril 25, 2023 | finance.yahoo.comRigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 25, 2023 | finance.yahoo.comRigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business UpdateApril 21, 2023 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is favoured by institutional owners who hold 55% of the companyApril 16, 2023 | finance.yahoo.com12 Best Low-Priced Growth Stocks To BuySee More Headlines RIGL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RIGL Company Calendar Last Earnings3/07/2023Today6/07/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RIGL CUSIP76655960 CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees165Year Founded1996Price Target and Rating Average Stock Price Forecast$4.21 High Stock Price Forecast$15.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+169.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,570,000.00 Net Margins-34.47% Pretax Margin-34.47% Return on Equity-2,419.00% Return on Assets-35.62% Debt Debt-to-Equity RatioN/A Current Ratio2.35 Quick Ratio2.11 Sales & Book Value Annual Sales$120.24 million Price / Sales2.25 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-19.50Miscellaneous Outstanding Shares173,670,000Free Float162,500,000Market Cap$270.93 million OptionableOptionable Beta0.72 Social Links Key ExecutivesRaul R. RodriguezPresident, Chief Executive Officer & DirectorDean L. SchornoChief Financial Officer & Executive Vice PresidentEsteban S. MasudaExecutive Vice President-ResearchDavid A. SantosChief Commercial Officer & Executive VPRaymond J. FureySecretary, Executive VP & General CounselKey CompetitorsSpectrum PharmaceuticalsNASDAQ:SPPIXOMANASDAQ:XOMAVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsPutnam Investments LLCBought 263,716 shares on 5/22/2023Ownership: 0.152%JPMorgan Chase & Co.Bought 350,799 shares on 5/18/2023Ownership: 0.301%New York State Common Retirement FundSold 68,100 shares on 5/18/2023Ownership: 0.019%Jane Street Group LLCBought 23,536 shares on 5/16/2023Ownership: 0.074%Susquehanna International Group LLPBought 34,200 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RIGL Stock - Frequently Asked Questions Should I buy or sell Rigel Pharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares. View RIGL analyst ratings or view top-rated stocks. What is Rigel Pharmaceuticals' stock price forecast for 2023? 7 Wall Street research analysts have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their RIGL share price forecasts range from $1.00 to $15.00. On average, they predict the company's share price to reach $4.21 in the next year. This suggests a possible upside of 169.8% from the stock's current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts. How have RIGL shares performed in 2023? Rigel Pharmaceuticals' stock was trading at $1.50 on January 1st, 2023. Since then, RIGL stock has increased by 4.0% and is now trading at $1.56. View the best growth stocks for 2023 here. When is Rigel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our RIGL earnings forecast. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Tuesday, March, 7th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. The biotechnology company had revenue of $51.28 million for the quarter, compared to analysts' expectations of $37.55 million. Rigel Pharmaceuticals had a negative net margin of 34.47% and a negative trailing twelve-month return on equity of 2,419.00%. During the same quarter in the previous year, the company earned ($0.13) EPS. What ETFs hold Rigel Pharmaceuticals' stock? ETFs with the largest weight of Rigel Pharmaceuticals (NASDAQ:RIGL) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO? 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). What is Rigel Pharmaceuticals' stock symbol? Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL." Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.80%), BlackRock Inc. (8.13%), Acadian Asset Management LLC (2.14%), State Street Corp (1.98%), Geode Capital Management LLC (1.89%) and FMR LLC (1.63%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rigel Pharmaceuticals' stock price today? One share of RIGL stock can currently be purchased for approximately $1.56. How much money does Rigel Pharmaceuticals make? Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $270.93 million and generates $120.24 million in revenue each year. The biotechnology company earns $-58,570,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. How many employees does Rigel Pharmaceuticals have? The company employs 165 workers across the globe. How can I contact Rigel Pharmaceuticals? Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101. This page (NASDAQ:RIGL) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.